Sermo exits financial services

Sermo has nixed its financial services offering, cutting headcount sharply as a result, and is doubling down on its pharma business.

Xconomy reported in December that Sermo laid off 30—nearly half of its staff. CEO Daniel Palestrant did not affirm that number but confirmed layoffs.  

“When we looked at where the growth was, we decided pharmas are adapting quicker than financial services and are obviously a bigger market. We took a headcount reduction rather than accept more money,” he said.
Growth in the startup's pharma roster has enabled Sermo to add back some staff. He said the firm will reach profitability in 2010.
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.